P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY

• N. L. Bartlett,
• C. A. Yasenchak,
• K. K. Ashraf,
• W. N. Harwin,
• J. Orcutt,
• P. Kuriakose,
• P. L. Zinzani,
• A. Mamidipalli,
• K. Fenton,
• C. Glenn,
• G. Nowakowski

Affiliations

N. L. Bartlett

1 Washington University School of Medicine, St. Louis, MO

C. A. Yasenchak

2 Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

K. K. Ashraf

3 Hem-Onc Assocs, Birmingham, AL

W. N. Harwin

4 Florida Cancer Specialists and Research Institute, Fort Myers, FL

J. Orcutt

5 Charleston Hematology Oncology Associates, Charleston, SC

P. Kuriakose

6 Henry Ford Health System, Detroit, MI, United States of America

P. L. Zinzani

7 Institute of Hematology “L. e A. Seràgnoli”, University of Bologna

A. Mamidipalli

9 Seagen Inc., Bothell, WA

K. Fenton

9 Seagen Inc., Bothell, WA

C. Glenn

9 Seagen Inc., Bothell, WA

G. Nowakowski

10 Division of Hematology, Mayo Clinic, Rochester, MN, United States of America